USPTO serial 79329099
EMPRANDO
Reviewed by CopyMark Law Group
Reg. 6926967Status 404
- Filing date
- Status date
- Registration date
- Dec 20, 2022
- Examiner
- BUKER, RACHEL EVE
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with EMPRANDO?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Maury M. Tepper, III
Maury M. Tepper, III Tepper & Eyster, PLLC3724 BENSON DRRALEIGH, NC 27609UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthma; vaccines | SECTION 70 - CANCELLED | — |
| 010 | Medical injection devices for the administration of pharmaceutical preparations for the delivery of anti-infectives, anti-inflammatories, antibacterial pharmaceuticals, antifungal preparations, antivirals, cardiovascular pharmaceuticals, dermatological pharmaceutical preparations, pharmaceutical preparations acting on the central nervous system, pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases, pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system, pharmaceutical preparations for use in hematology and in tissue and organ transplantation, pharmaceutical preparations for the prevention and treatment of eye diseases and conditions, pharmaceutical preparations for the prevention and treatment of heart rhythm disorders, pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders, pharmaceutical preparations for the prevention and treatment of kidney diseases, pharmaceutical preparations for the prevention and treatment of diabetes, pharmaceutical preparations for the prevention and treatment of hypertension, pharmaceutical preparations for the prevention and treatment of skin disorders, pharmaceutical preparations for use in dermatology, pharmaceutical preparations for use in urology, pharmaceutical preparations for use in ophthalmology, pharmaceutical preparations for the prevention and treatment of cancer and tumors, pharmaceutical preparations for the prevention and treatment of allergies, pharmaceutical preparations for the prevention and treatment of bone diseases, pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthma and vaccines | SECTION 70 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 31, 2024 | DENA | NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED | — |
| Aug 31, 2024 | DETH | DEATH OF INTERNATIONAL REGISTRATION | — |
| Apr 24, 2023 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Apr 5, 2023 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Apr 5, 2023 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Mar 20, 2023 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Dec 20, 2022 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Dec 20, 2022 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Oct 4, 2022 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Oct 4, 2022 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Oct 3, 2022 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Sep 14, 2022 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Sep 14, 2022 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Sep 14, 2022 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Aug 31, 2022 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 16, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 27, 2022 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 27, 2022 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 27, 2022 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 27, 2022 | RFNP | REFUSAL PROCESSED BY IB | — |
| Mar 8, 2022 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Mar 8, 2022 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Feb 9, 2022 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Feb 8, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 7, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 26, 2022 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Jan 26, 2022 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jan 26, 2022 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Jan 26, 2022 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 26, 2022 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jan 26, 2022 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Jan 11, 2022 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jan 7, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jan 5, 2022 | LIMI | LIMITATION FROM ORIGINAL APPLICATION ENTERED | — |
| Dec 23, 2021 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |